Confirmatory Efficacy of the Building a Strong Identity and Coping Skills Program
Penn State University · NCT05789446
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 11+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 360
- US sites recruiting
- 3
- Study start
- February 1, 2025
- Record last updated
- September 17, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this clinical trial is to the efficacy of the Building a Strong Identity and Coping Skills intervention within a sample of low-income and minoritized youth aged 11-14 who are seeking mental health treatment and have been placed on a waitlist to receive services.
The aims of this study are to: (1) confirm the efficacy of BaSICS by replicating previous findings, (2) Examine the changes of coping mechanisms and symptom change over the course of the BaSICS intervention, and (3) test models of physiologic stress reactivity and regulation to capture biological "risk" and recalibration.
Cohorts of 20 participants will randomly be enrolled in either the intervention (10) or control (10) groups. Participants enrolled in the intervention group will complete the BaSICS program and participants enrolled in the no intervention group will not be enrolled in the intervention program. The BaSICS program is designed to help treat anxiety, depression, and post-traumatic stress symptoms and disorders and have direct effects on physiologic stress response systems (hypothalamic-pituitary-adrenal (HPA) axis). Researchers will compare the intervention and no intervention groups to see if there is a difference in the reduction of markers for anxiety, depression, and suicide scores, changes in coping mechanism, and HPA reactivity profiles
Being studied: Building a Strong Identity and Coping Skills
Conditions: Chronic Stress; Anxiety; Depression
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Children ages 11-14 at intake
- Family income at or below 200% federal poverty level
- Child speaks English
- Parent speaks English or Spanish
Exclusion Criteria
- Intellectual disability
- Autism spectrum disorder
- High suicidal risk (score of 17 or more on the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-Kid))
- Severe depression (score of 19 or more on Patient health questionnaire (PHQ).
Recruiting US locations
Penn State Health Medical Group - Psychiatry and Behavioral Health
Hershey, PA 17033
Site contact: Dara Babinski, PhD · dbabinski@pennstatehealth.psu.edu
Dr. Edwin L. Herr Clinic
State College, PA 16802
Site contact: Kristen Nadermann, PhD · kmc452@psu.edu
Penn State Psychological Clinic
State College, PA 16802
Site contact: Estee Hausman, PhD · exh471@psu.edu
Study contacts (from the official record)
- Martha E Wadsworth, PhD · 814-865-2878 · mew27@psu.edu
- Dara Babinksi, PhD · dbabinski@pennstatehealth.psu.edu
Similar studies in Pennsylvania
All mental health studies in Pennsylvania →- RecruitingHealthy volunteers
Observational Study of Decentralized Urine Optical Interaction Patterns Associated With Environmental Microplastic and Nanoplastic Exposure
Ecotera Health LLC
- Location
- Philadelphia, PA + 50 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteers
Pupillometry in Identifying Risk of Postoperative Opioid-induced Respiratory Depression in Children Undergoing Tonsillectomy
NeurOptics Inc
- Location
- Pittsburgh, PA
- Eligibility basics
- Ages 3–17
- RecruitingPhase 3
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
Definium Therapeutics US, Inc.
- Location
- Philadelphia, PA + 22 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 3
A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- Philadelphia, PA + 19 other US sites
- Eligibility basics
- Ages 18+